Hanneke discusses the competitive landscape of vaccine development, likening it to young mothers comparing their children’s milestones. She emphasizes the importance of safety and efficacy, expressing confidence in the FDA’s rigorous approach. While she would take a vaccine if available, she believes frontline workers should be prioritized for initial access, predicting that general public availability may come in Q2.
